Physician profile
Paul Kang
NPI 1487680070
$39,527.17
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,540 · 2020: $2,241 · 2021: $2,216 · 2022: $2,385 · 2023: $12K · 2024: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $1,475 · Food and Beverage: $679 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,972.90 |
| Travel and Lodging | $1,475.31 |
| Food and Beverage | $678.86 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $16,218.99 | 2019-2024 | Tecnis Iol, Tecnis Simplicity |
| Carl Zeiss Meditec, INC. | $8,457.10 | 2019-2024 | Cirrus Hd-Oct, Clarus, Visumax |
| Shire North American Group INC | $4,714.61 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $3,620.63 | 2019-2021 | |
| Allergan, INC. | $2,011.47 | 2019 | |
| Aerie Pharmaceuticals, INC. | $1,558.80 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $1,040.94 | 2024 | |
| New World Medical,INC. | $812.97 | 2022 | |
| Lensar, INC. | $700.00 | 2021 | |
| Rxsight INC | $135.17 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $64.94 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $60.47 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $59.69 | 2019-2021 | |
| Alcon Vision LLC | $35.23 | 2021 | |
| Glaukos Corporation | $18.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.